| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:Abetimus
CAS:167362-48-3
Package:5mg;50mg
|
|
| | AbetiMus Basic information |
| | AbetiMus Chemical Properties |
| | AbetiMus Usage And Synthesis |
| Uses | Abetimus (LJP 394 free base) is an immunosuppressant consisting of four double-stranded DNA (dsDNA) oligonucleotides. Abetimus is capable of crosslinking anti-dsDNA antibodies on the surface of B cells, and decreases anti-dsDNA antibodies levels. Abetimus has the potential for research of systemic lupus erythematosus[1]. | | in vivo | Abetimus (LJP 394 free base) proves effective in suppressing anti-dsDNA-mediated pathologies in male BXSB mice, a model for systemic lupus. Mice dosed with Abetimus (3-300 μg/mouse) i.v. twice weekly, starting around nine weeks of age, has significantly lower titers of anti-dsDNA, lower numbers of anti-dsDNA-secreting spleen cells and less adverse renal histopathology than control mice[2].
Abetimus has a pharmacokinetic half-life ranging from 40 min to 1 h in mice[1]. | | References | [1] Marta Mosca, et al. LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus. Expert Opin Pharmacother. 2007 Apr;8(6):873-9. DOI:10.1517/14656566.8.6.873
[2] S M Coutts, et al. Pharmacological intervention in antibody mediated disease. Lupus. 1996 Apr;5(2):158-9. DOI:10.1177/096120339600500214 |
| | AbetiMus Preparation Products And Raw materials |
|